Mangalaganesh, Shruthi

At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron Variant

Singanallur, N. B., van Vuren, P. J., McAuley, A. J., Bruce, M. P., Kuiper, M. J., Gwini, S. M., Riddell, S., Goldie, S., Drew, T. W., Blasdell, K. R., et al. (2022) · Frontiers in Immunology

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 15

At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron Variant

Singanallur, N. B., van Vuren, P. J., McAuley, A. J., Bruce, M. P., Kuiper, M. J., Gwini, S. M., Riddell, S., Goldie, S., Drew, T. W., Blasdell, K. R., et al. (2022) · Frontiers in Immunology

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 15

“But Mouse, You Are Not Alone”: On Some Severe Acute Respiratory Syndrome Coronavirus 2 Variants Infecting Mice

Kuiper, M. J., Wilson, L. O. W., Mangalaganesh, S., Lee, C., Reti, D., & Vasan, S. S. (2021) · ILAR Journal

SARS-CoV-2 and COVID-19 ResearchZoonotic diseases and public health

Cited by 14

Highly Thermotolerant SARS-CoV-2 Vaccine Elicits Neutralising Antibodies Against Delta and Omicron in Mice

van Vuren, P. J., McAuley, A. J., Kuiper, M. J., Singanallur, N. B., Bruce, M. P., Riddell, S., Goldie, S., Mangalaganesh, S., Chahal, S., Drew, T. W., et al. (2022) · Viruses

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 9